References
- Bathala MS, Masumoto H, Oguma T, et al. (2012). Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 40:2250–5
- Bounameaux H, Camm AJ. (2014). Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74:1209–31
- Bristol-Myers Squibb. (2011). Coumadin® (warfarin sodium) [package Insert]. Princeton (NJ): Bristol-Myers Squibb
- Daiichi Sankyo Co. Ltd. (2014). LIXIANA® edoxaban tosilate hydrate tablets [package insert]. Tokyo, Japan: Daiichi Sankyo Co. Ltd
- Daiichi Sankyo Inc. (2015). SAVAYSATM (edoxaban) tablets for oral use, Full Prescribing Information. Parsippany (NJ): Daiichi Sankyo Inc
- European medicines agency. (1998). ICH Topic E5 (R1), Ethnic factors in the acceptability of foreign clinical data. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf [last accessed 27 Jun 2016]
- Furugohri T, Isobe K, Honda Y, et al. (2008). DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542–9
- Lloyd-Jones DM, Wang TJ, Leip EP, et al. (2004). Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 110:1042–6
- Matsushima N, Lee F, Sato T, et al. (2013). Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev 2:358–66
- Mendell J, Tachibana M, Shi M, Kunitada S. (2011). Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51:687–94
- Ogata K, Mendell-Harary J, Tachibana M, et al. (2010). Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–53
- Parasrampuria DA, Truitt KE. (2016). Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 55:641–55
- Shi J, Wang X, Eyler RF, et al. (2016). Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms. Basic Clin Pharmacol Toxicol. [Epub ahead of print]. doi: 10.1111/bcpt.12625
- Wolf PA, Abbott RD, Kannel WB. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983–8
- Yin OQ, Miller R. (2014). Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig 34:743–52